Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 07 2022
Historique:
received: 31 01 2022
accepted: 30 06 2022
entrez: 15 7 2022
pubmed: 16 7 2022
medline: 20 7 2022
Statut: epublish

Résumé

Digital health technologies enable remote and therefore frequent measurement of motor signs, potentially providing reliable and valid estimates of motor sign severity and progression in Parkinson's disease (PD). The Roche PD Mobile Application v2 was developed to measure bradykinesia, bradyphrenia and speech, tremor, gait and balance. It comprises 10 smartphone active tests (with ½ tests administered daily), as well as daily passive monitoring via a smartphone and smartwatch. It was studied in 316 early-stage PD participants who performed daily active tests at home then carried a smartphone and wore a smartwatch throughout the day for passive monitoring (study NCT03100149). Here, we report baseline data. Adherence was excellent (96.29%). All pre-specified sensor features exhibited good-to-excellent test-retest reliability (median intraclass correlation coefficient = 0.9), and correlated with corresponding Movement Disorder Society-Unified Parkinson's Disease Rating Scale items (rho: 0.12-0.71). These findings demonstrate the preliminary reliability and validity of remote at-home quantification of motor sign severity with the Roche PD Mobile Application v2 in individuals with early PD.

Identifiants

pubmed: 35840753
doi: 10.1038/s41598-022-15874-4
pii: 10.1038/s41598-022-15874-4
pmc: PMC9287320
doi:

Banques de données

ClinicalTrials.gov
['NCT03100149']

Types de publication

Clinical Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12081

Informations de copyright

© 2022. The Author(s).

Références

NPJ Parkinsons Dis. 2021 Mar 5;7(1):24
pubmed: 33674597
Eur Neurol. 2018;79(3-4):206-210
pubmed: 29597229
Expert Rev Neurother. 2019 Dec;19(12):1191-1200
pubmed: 31343928
Sci Rep. 2021 Jan 15;11(1):1632
pubmed: 33452324
Eur Geriatr Med. 2020 Jun;11(3):417-426
pubmed: 32297254
Mov Disord Clin Pract. 2015 Oct 20;3(1):59-64
pubmed: 30363542
Gait Posture. 2007 Jul;26(2):172-8
pubmed: 17532636
J Clin Neurosci. 2013 Jun;20(6):827-30
pubmed: 23639618
J Parkinsons Dis. 2017;7(1):65-77
pubmed: 28222539
J Acoust Soc Am. 2011 Jan;129(1):350-67
pubmed: 21303016
Mov Disord Clin Pract. 2016 Aug 03;4(3):316-322
pubmed: 30363442
Sci Transl Med. 2019 Nov 27;11(520):
pubmed: 31776289
Ann Clin Transl Neurol. 2019 Aug;6(8):1498-1509
pubmed: 31402628
Front Neurol. 2021 Oct 01;12:705407
pubmed: 34659081
Mov Disord. 2008 Mar 15;23(4):531-7
pubmed: 18074362
Ann Biomed Eng. 2017 Nov;45(11):2614-2625
pubmed: 28852889
NPJ Digit Med. 2020 Jul 23;3:97
pubmed: 32715091
J Alzheimers Dis. 2018;66(1):229-237
pubmed: 30282359
IEEE Trans Biomed Eng. 2020 Dec;67(12):3491-3500
pubmed: 32324537
Sci Data. 2016 Mar 03;3:160011
pubmed: 26938265
Mov Disord. 2016 Sep;31(9):1272-82
pubmed: 27125836
Mov Disord. 2003 Jul;18(7):738-50
pubmed: 12815652
J Neuroeng Rehabil. 2016 Apr 19;13:39
pubmed: 27094039
Parkinsonism Relat Disord. 2015 Jun;21(6):650-3
pubmed: 25819808
Br J Clin Pharmacol. 2021 Sep;87(9):3608-3618
pubmed: 33580584
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
J Neurol. 2019 Aug;266(8):1927-1936
pubmed: 31073716
Hum Mov Sci. 2019 Jun;65:
pubmed: 30145024
NPJ Parkinsons Dis. 2020 Dec 8;6(1):36
pubmed: 33293531
Neurodegener Dis Manag. 2020 Jun;10(3):137-157
pubmed: 32571150
Neurology. 2018 Oct 16;91(16):e1528-e1538
pubmed: 30232246
Sensors (Basel). 2020 Aug 04;20(15):
pubmed: 32759667
Front Neurol. 2018 Dec 12;9:1036
pubmed: 30619024
Physiol Meas. 2020 Jun 19;41(5):054002
pubmed: 32259798
J Parkinsons Dis. 2021;11(s1):S111-S115
pubmed: 33459666
Alzheimer Dis Assoc Disord. 2016 Apr-Jun;30(2):127-33
pubmed: 25850732
Mov Disord. 2017 May;32(5):789-793
pubmed: 28218413
Mov Disord. 2018 Aug;33(8):1287-1297
pubmed: 29701258
Front Neurol. 2018 Mar 06;9:121
pubmed: 29568281
J Neuroeng Rehabil. 2012 Aug 22;9:59
pubmed: 22913719
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Lancet Neurol. 2009 Dec;8(12):1158-71
pubmed: 19909914
Mov Disord Clin Pract. 2020 Apr 30;7(6):629-638
pubmed: 32775508
J Neurol Sci. 2016 Sep 15;368:337-42
pubmed: 27538660
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Neurosci Lett. 2018 Nov 20;687:248-252
pubmed: 30287303
Gait Posture. 2012 Jul;36(3):471-6
pubmed: 22750016
PLoS One. 2016 Oct 12;11(10):e0162799
pubmed: 27732597
Mov Disord. 2019 May;34(5):657-663
pubmed: 30901495
Front Neurol. 2017 Sep 06;8:435
pubmed: 28932206
Gait Posture. 2012 Mar;35(3):373-7
pubmed: 22098825
Front Psychiatry. 2020 Sep 16;11:574375
pubmed: 33192706
PLoS One. 2016 Jul 28;11(7):e0158852
pubmed: 27467066
IEEE Trans Neural Syst Rehabil Eng. 2010 Jun;18(3):303-10
pubmed: 20388604
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184
JAMA Neurol. 2018 Jul 1;75(7):876-880
pubmed: 29582075
Psychiatry Res. 2016 Apr 30;238:189-195
pubmed: 27086232
NeuroRehabilitation. 2015;37(1):3-10
pubmed: 26409689
Mov Disord. 2018 May;33(5):771-782
pubmed: 29572948
PLoS One. 2015 Sep 17;10(9):e0138095
pubmed: 26379170
Sensors (Basel). 2015 Sep 17;15(9):23727-44
pubmed: 26393595

Auteurs

Florian Lipsmeier (F)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland. florian.lipsmeier@roche.com.

Kirsten I Taylor (KI)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Ronald B Postuma (RB)

Department of Neurology, McGill University, Montreal General Hospital, Montreal, QC, Canada.

Ekaterina Volkova-Volkmar (E)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Timothy Kilchenmann (T)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Brit Mollenhauer (B)

Paracelsus-Elena-Klinik, Kassel, Germany.
Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.

Atieh Bamdadian (A)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Werner L Popp (WL)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Wei-Yi Cheng (WY)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Yan-Ping Zhang (YP)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Detlef Wolf (D)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Jens Schjodt-Eriksen (J)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Anne Boulay (A)

Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

Hanno Svoboda (H)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Wagner Zago (W)

Prothena Biosciences Inc, South San Francisco, CA, USA.

Gennaro Pagano (G)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Michael Lindemann (M)

Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH